Provention Bio, Inc. - Common Stock (NQ:PRVB)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Provention Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? ↗

June 15, 2023

Company Moves Ahead With Drug Development

Via Benzinga

Provention Bio Inc. (NASDAQ: PRVB) Highlighted for Surprising Price Action

April 26, 2023

Via Investor Brand Network

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗

April 12, 2023

Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...

Via Benzinga

Is Sanofi Stock a Buy Now? ↗

March 25, 2023

The pharma giant has outperformed the broader market over the past 12 months.

Via The Motley Fool

Provention Bio's Earnings Outlook ↗

March 15, 2023

Via Benzinga

4 Analysts Have This to Say About Provention Bio ↗

March 14, 2023

Via Benzinga

Provention Bio, Inc. (NASDAQ: PRVB) Making Surprising Moves in Monday Session

March 13, 2023

Via Investor Brand Network

Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information ↗

April 11, 2023

Via Benzinga

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

March 29, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 23, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi ↗

March 13, 2023

Via Benzinga

Top 5 Health Care Stocks That May Crash In March ↗

March 22, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

Why Provention Bio Stock Skyrocketed 256% This Week ↗

March 16, 2023

Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.

Via The Motley Fool

Why Shares of MacroGenics Climbed Thursday ↗

March 16, 2023

The cancer-focused biotech delivered a strong earnings report.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023 ↗

March 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗

March 14, 2023

Via Benzinga

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

March 13, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners ↗

March 13, 2023

On a volatile market day, companies are still looking for smart combinations.

Via The Motley Fool

Nasdaq Up 150 Points; Gold Rises Over 2% ↗

March 13, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 150 points on Monday. The Dow traded up 0.59% to 32,096.68 while the NASDAQ rose 1.35% to 11,288.8. The S&P...

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 13, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion

March 13, 2023

Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 13, 2023

Via Benzinga

Dow Jumps 300 Points; Crude Oil Down 1% ↗

March 13, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 300 points on Monday. The Dow traded up 0.94% to 32,210.33 while the NASDAQ rose 1.52% to 11,307.74. The S&P 500,...

Via Benzinga

Illumina, Seagen And Other Big Stocks Moving Higher On Monday ↗

March 13, 2023

U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.

Via Benzinga

US Stocks Mostly Higher; Dow Rises 75 Points ↗

March 13, 2023

U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose...

Via Benzinga

Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal ↗

March 13, 2023

Pfizer expects Seagen to add at least $10 billion to its topline in 2030.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.